Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04594707




Registration number
NCT04594707
Ethics application status
Date submitted
15/10/2020
Date registered
20/10/2020
Date last updated
16/05/2024

Titles & IDs
Public title
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Scientific title
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
2020-001429-30
Secondary ID [2] 0 0
WA42294
Universal Trial Number (UTN)
Trial acronym
STARSCAPE-OLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PRM-151 (Zinpentraxin Alfa)

Experimental: Zinpentraxin Alfa - Corhort A: Participants entering, following participation in study PRM-151-202.

Cohort B: Participants entering, following participation in study WA42293.


Treatment: Drugs: PRM-151 (Zinpentraxin Alfa)
Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.

Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Adverse Events (AEs)
Timepoint [1] 0 0
From baseline until 8 weeks after the final dose, an average of 6 months
Primary outcome [2] 0 0
Percentage of Participants With Infusion Related Reactions (IRRs) and Other AEs of Special Interest
Timepoint [2] 0 0
From baseline until 8 weeks after the final dose, an average of 6 months
Primary outcome [3] 0 0
Percentage of of Participants Permanently Discontinuing Study Treatment Due to AEs
Timepoint [3] 0 0
From baseline until 8 weeks after the final dose, an average of 6 months
Secondary outcome [1] 0 0
Annual Rate of Change in Forced Vital Capacity (FVC) (mL)
Timepoint [1] 0 0
From baseline until study completion (up to approximately 1.5 years)
Secondary outcome [2] 0 0
Annual Rate of Change in 6-Minute Walk Distance (6MWD)
Timepoint [2] 0 0
From baseline until study completion (up to approximately 1.5 years)
Secondary outcome [3] 0 0
Annual Rate of Change in FVC% Predicted
Timepoint [3] 0 0
From baseline until study completion (up to approximately 1.5 years)
Secondary outcome [4] 0 0
Change in Carbon Monoxide Diffusing Capacity (DLCO)
Timepoint [4] 0 0
At Baseline, Week 24 and Week 48
Secondary outcome [5] 0 0
Time to Disease Progression
Timepoint [5] 0 0
From baseline until study completion (up to approximately 1.5 years)
Secondary outcome [6] 0 0
Survival
Timepoint [6] 0 0
Every 6 Months and at study completion (up to approximately 1.5 years)
Secondary outcome [7] 0 0
IPF-related Mortality
Timepoint [7] 0 0
Every 6 Months and at study completion (up to approximately 1.5 years)
Secondary outcome [8] 0 0
Respiratory-related Mortality
Timepoint [8] 0 0
Every 6 Months and at study completion (up to approximately 1.5 years)
Secondary outcome [9] 0 0
Plasma Concentrations of PRM-151 at Specified Timepoints
Timepoint [9] 0 0
Days 1 and 5, Weeks 4, and 12
Secondary outcome [10] 0 0
Prevalence of Anti-drug Antibodies (ADAs) to PRM-151 at Baseline
Timepoint [10] 0 0
Baseline (Day 1)
Secondary outcome [11] 0 0
Percentage of Participants With ADAs During the Study
Timepoint [11] 0 0
Weeks 4, 12 and 24

Eligibility
Key inclusion criteria
* Taken part in either of the prior PRM-151 studies: PRM-151-202 or WA42293.
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception.
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Acute respiratory or systemic bacterial, viral, or fungal infection at the first visit of the OLE, or within 2 weeks of the first visit for patients joining Cohort A (from Study PRM-151-202).
* History of smoking within 3 months prior to the first visit in the OLE.
* History of alcohol or substance use disorder within 2 years prior to the first visit of the OLE or known or suspected active alcohol or substance-use disorder.
* History of severe allergic reaction or anaphylactic reaction to PRM-151.
* Clinically significant abnormality on ECG during eligibility assessment that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant.
* Prolonged corrected QT interval > 450 ms (for men) or > 470 ms (for women) based on the Fridericia correction formula.
* Clinically significant laboratory test abnormalities (hematology, serumchemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk in administering study drug to the participant.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/08/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/02/2023
Sample size
Target
Accrual to date
Final
117
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Cairns Base Hospital; Cancer Care Centre - Cairns
Recruitment hospital [3] 0 0
Lung Research Queensland - Nundah
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [5] 0 0
Monash Medical Centre; Medicine - Melbourne
Recruitment hospital [6] 0 0
The Alfred Hospital - Prahan
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4870 - Cairns
Recruitment postcode(s) [3] 0 0
4101 - Nundah
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
3186 - Melbourne
Recruitment postcode(s) [6] 0 0
3181 - Prahan
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Autonoma Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Córdoba
Country [26] 0 0
Argentina
State/province [26] 0 0
Derqui-Pilar
Country [27] 0 0
Argentina
State/province [27] 0 0
Florida, Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Mar Del Plata
Country [29] 0 0
Argentina
State/province [29] 0 0
Mendoza, Mendoza City
Country [30] 0 0
Argentina
State/province [30] 0 0
Mendoza
Country [31] 0 0
Argentina
State/province [31] 0 0
Rosario
Country [32] 0 0
Argentina
State/province [32] 0 0
San Miguel de Tucuman
Country [33] 0 0
Belgium
State/province [33] 0 0
Brussels
Country [34] 0 0
Belgium
State/province [34] 0 0
Bruxelles
Country [35] 0 0
Belgium
State/province [35] 0 0
Leuven
Country [36] 0 0
Belgium
State/province [36] 0 0
Liège
Country [37] 0 0
Belgium
State/province [37] 0 0
Yvoir
Country [38] 0 0
Canada
State/province [38] 0 0
Alberta
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
China
State/province [42] 0 0
Beijing City
Country [43] 0 0
China
State/province [43] 0 0
Beijing Shi
Country [44] 0 0
China
State/province [44] 0 0
Changsha
Country [45] 0 0
China
State/province [45] 0 0
ShenYang
Country [46] 0 0
China
State/province [46] 0 0
Shijiazhuang City
Country [47] 0 0
China
State/province [47] 0 0
Tianjin
Country [48] 0 0
China
State/province [48] 0 0
Wuhan City
Country [49] 0 0
China
State/province [49] 0 0
Wuxi
Country [50] 0 0
China
State/province [50] 0 0
Zhengzhou
Country [51] 0 0
Czechia
State/province [51] 0 0
Brno
Country [52] 0 0
Czechia
State/province [52] 0 0
Hradec Kralove
Country [53] 0 0
Czechia
State/province [53] 0 0
Praha 4
Country [54] 0 0
Czechia
State/province [54] 0 0
Zlin
Country [55] 0 0
Denmark
State/province [55] 0 0
Hellerup
Country [56] 0 0
Denmark
State/province [56] 0 0
Odense C
Country [57] 0 0
France
State/province [57] 0 0
Bobigny
Country [58] 0 0
France
State/province [58] 0 0
Brest
Country [59] 0 0
France
State/province [59] 0 0
Bron
Country [60] 0 0
France
State/province [60] 0 0
CHU Hopitaux De Bordeaux
Country [61] 0 0
France
State/province [61] 0 0
Dijon
Country [62] 0 0
France
State/province [62] 0 0
La Tronche
Country [63] 0 0
France
State/province [63] 0 0
Lille
Country [64] 0 0
France
State/province [64] 0 0
Marseille
Country [65] 0 0
France
State/province [65] 0 0
Nice
Country [66] 0 0
France
State/province [66] 0 0
Paris
Country [67] 0 0
France
State/province [67] 0 0
Reims
Country [68] 0 0
France
State/province [68] 0 0
Rennes
Country [69] 0 0
France
State/province [69] 0 0
Tours
Country [70] 0 0
Germany
State/province [70] 0 0
Berlin
Country [71] 0 0
Germany
State/province [71] 0 0
Heidelberg
Country [72] 0 0
Germany
State/province [72] 0 0
Immenhausen
Country [73] 0 0
Germany
State/province [73] 0 0
Marburg
Country [74] 0 0
Germany
State/province [74] 0 0
Münnerstadt
Country [75] 0 0
Germany
State/province [75] 0 0
Solingen
Country [76] 0 0
Greece
State/province [76] 0 0
Athens
Country [77] 0 0
Greece
State/province [77] 0 0
Chaidari
Country [78] 0 0
Greece
State/province [78] 0 0
Heraklio
Country [79] 0 0
Greece
State/province [79] 0 0
Ioannina
Country [80] 0 0
Greece
State/province [80] 0 0
Marousi
Country [81] 0 0
Greece
State/province [81] 0 0
Mezourlo
Country [82] 0 0
Greece
State/province [82] 0 0
Patras
Country [83] 0 0
Greece
State/province [83] 0 0
Sotiria Athens
Country [84] 0 0
Greece
State/province [84] 0 0
Thessaloniki
Country [85] 0 0
Hong Kong
State/province [85] 0 0
Hong Kong
Country [86] 0 0
Hungary
State/province [86] 0 0
Budapest
Country [87] 0 0
Hungary
State/province [87] 0 0
Debrecen
Country [88] 0 0
Hungary
State/province [88] 0 0
Szombathely
Country [89] 0 0
Hungary
State/province [89] 0 0
Tatabánya
Country [90] 0 0
Hungary
State/province [90] 0 0
Törökbálint
Country [91] 0 0
Israel
State/province [91] 0 0
Ashkelon
Country [92] 0 0
Israel
State/province [92] 0 0
Be'er Ya'akov
Country [93] 0 0
Israel
State/province [93] 0 0
Beer sheva
Country [94] 0 0
Israel
State/province [94] 0 0
Haifa
Country [95] 0 0
Israel
State/province [95] 0 0
Holon
Country [96] 0 0
Israel
State/province [96] 0 0
Jerusalem
Country [97] 0 0
Israel
State/province [97] 0 0
Kfar- Saba
Country [98] 0 0
Israel
State/province [98] 0 0
Petach Tiqwa
Country [99] 0 0
Israel
State/province [99] 0 0
Ramat Gan
Country [100] 0 0
Israel
State/province [100] 0 0
Rehovot
Country [101] 0 0
Israel
State/province [101] 0 0
Tel Aviv
Country [102] 0 0
Italy
State/province [102] 0 0
Abruzzo
Country [103] 0 0
Italy
State/province [103] 0 0
Campania
Country [104] 0 0
Italy
State/province [104] 0 0
Emilia-Romagna
Country [105] 0 0
Italy
State/province [105] 0 0
Lazio
Country [106] 0 0
Italy
State/province [106] 0 0
Lombardia
Country [107] 0 0
Italy
State/province [107] 0 0
Puglia
Country [108] 0 0
Italy
State/province [108] 0 0
Sardegna
Country [109] 0 0
Italy
State/province [109] 0 0
Sicilia
Country [110] 0 0
Italy
State/province [110] 0 0
Toscana
Country [111] 0 0
Italy
State/province [111] 0 0
Veneto
Country [112] 0 0
Japan
State/province [112] 0 0
Aichi
Country [113] 0 0
Japan
State/province [113] 0 0
Chiba
Country [114] 0 0
Japan
State/province [114] 0 0
Fukuoka
Country [115] 0 0
Japan
State/province [115] 0 0
Hyogo
Country [116] 0 0
Japan
State/province [116] 0 0
Kamogawa
Country [117] 0 0
Japan
State/province [117] 0 0
Kanagawa
Country [118] 0 0
Japan
State/province [118] 0 0
Kawasaki-Shi
Country [119] 0 0
Japan
State/province [119] 0 0
Kumamoto-Shi
Country [120] 0 0
Japan
State/province [120] 0 0
Nagasaki
Country [121] 0 0
Japan
State/province [121] 0 0
Naka-gun
Country [122] 0 0
Japan
State/province [122] 0 0
Okayama
Country [123] 0 0
Japan
State/province [123] 0 0
Sakai-shi
Country [124] 0 0
Japan
State/province [124] 0 0
Seto-shi
Country [125] 0 0
Japan
State/province [125] 0 0
Tenri-Shi
Country [126] 0 0
Japan
State/province [126] 0 0
Tochigi
Country [127] 0 0
Japan
State/province [127] 0 0
Tokushima
Country [128] 0 0
Japan
State/province [128] 0 0
Tokyo
Country [129] 0 0
Korea, Republic of
State/province [129] 0 0
Gyeonggi-do
Country [130] 0 0
Korea, Republic of
State/province [130] 0 0
Namdong-gu
Country [131] 0 0
Korea, Republic of
State/province [131] 0 0
Seongnam-si
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Seoul
Country [133] 0 0
Mexico
State/province [133] 0 0
Mexico CITY (federal District)
Country [134] 0 0
Mexico
State/province [134] 0 0
Nuevo LEON
Country [135] 0 0
Mexico
State/province [135] 0 0
Chihuahua
Country [136] 0 0
Mexico
State/province [136] 0 0
Morelia
Country [137] 0 0
Netherlands
State/province [137] 0 0
Nieuwegein
Country [138] 0 0
Netherlands
State/province [138] 0 0
Rotterdam
Country [139] 0 0
New Zealand
State/province [139] 0 0
Auckland
Country [140] 0 0
New Zealand
State/province [140] 0 0
Christchurch
Country [141] 0 0
New Zealand
State/province [141] 0 0
Hamilton
Country [142] 0 0
New Zealand
State/province [142] 0 0
Tauranga
Country [143] 0 0
Norway
State/province [143] 0 0
Bergen
Country [144] 0 0
Norway
State/province [144] 0 0
Lørenskog
Country [145] 0 0
Norway
State/province [145] 0 0
Oslo
Country [146] 0 0
Poland
State/province [146] 0 0
Bia?ystok
Country [147] 0 0
Poland
State/province [147] 0 0
Bydgoszcz
Country [148] 0 0
Poland
State/province [148] 0 0
Lodz
Country [149] 0 0
Portugal
State/province [149] 0 0
Braga
Country [150] 0 0
Portugal
State/province [150] 0 0
Guimarães
Country [151] 0 0
Portugal
State/province [151] 0 0
Lisboa
Country [152] 0 0
Portugal
State/province [152] 0 0
Vila Nova de Gaia
Country [153] 0 0
Singapore
State/province [153] 0 0
Singapore
Country [154] 0 0
South Africa
State/province [154] 0 0
Cape Town
Country [155] 0 0
South Africa
State/province [155] 0 0
Somerset West
Country [156] 0 0
Spain
State/province [156] 0 0
Alava
Country [157] 0 0
Spain
State/province [157] 0 0
Asturias
Country [158] 0 0
Spain
State/province [158] 0 0
Barcelona
Country [159] 0 0
Spain
State/province [159] 0 0
Cantabria
Country [160] 0 0
Spain
State/province [160] 0 0
LA Coruña
Country [161] 0 0
Spain
State/province [161] 0 0
Madrid
Country [162] 0 0
Spain
State/province [162] 0 0
Vizcaya
Country [163] 0 0
Spain
State/province [163] 0 0
Granada
Country [164] 0 0
Spain
State/province [164] 0 0
Malaga
Country [165] 0 0
Spain
State/province [165] 0 0
Salamanca
Country [166] 0 0
Spain
State/province [166] 0 0
Valencia
Country [167] 0 0
Taiwan
State/province [167] 0 0
Chia-yi
Country [168] 0 0
Taiwan
State/province [168] 0 0
Kaoshiung City
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taichung
Country [170] 0 0
Taiwan
State/province [170] 0 0
Tainan
Country [171] 0 0
Taiwan
State/province [171] 0 0
Taipei
Country [172] 0 0
Taiwan
State/province [172] 0 0
Xitun Dist.
Country [173] 0 0
Turkey
State/province [173] 0 0
?stanbul
Country [174] 0 0
Turkey
State/province [174] 0 0
Adana
Country [175] 0 0
Turkey
State/province [175] 0 0
Ankara
Country [176] 0 0
Turkey
State/province [176] 0 0
Bursa
Country [177] 0 0
Turkey
State/province [177] 0 0
Gaziantep
Country [178] 0 0
Turkey
State/province [178] 0 0
Istanbul
Country [179] 0 0
Turkey
State/province [179] 0 0
Izmir
Country [180] 0 0
Turkey
State/province [180] 0 0
Kocaeli
Country [181] 0 0
Turkey
State/province [181] 0 0
Maltepe
Country [182] 0 0
Turkey
State/province [182] 0 0
Melikgazi/Kayser
Country [183] 0 0
Turkey
State/province [183] 0 0
Mersin
Country [184] 0 0
Turkey
State/province [184] 0 0
Muratpasa/Antalya
Country [185] 0 0
Turkey
State/province [185] 0 0
Sariyer

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).
Trial website
https://clinicaltrials.gov/study/NCT04594707
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04594707